Trials / Completed
CompletedNCT01154335
Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer
A Phase I Study of Everolimus (mTOR Inhibitor) and OSI-906 (Dual IGFR and IR Tyrosine Kinase Inhibitor) for the Treatment of Patients With Refractory Metastatic Colorectal Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- SCRI Development Innovations, LLC · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the maximum tolerated dose (MTD) of the combination of OSI-906 and everolimus for the treatment of patients with refractory metastatic colorectal cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | OSI-906 | Dose Level 1: 50 mg Twice a Day, cycle-28 days Dose Level 2: 100 mg Twice a Day, cycle-28 days Dose Level 2a: 100 mg Twice a Day, cycle-28 days |
| DRUG | Everolimus | Dose Level 1: 5mg Daily, cycle-28 days Dose Level 2: 10mg Daily, cycle-28 days Dose Level 2a: 5mg Daily, cycle-28 days |
Timeline
- Start date
- 2010-07-01
- Primary completion
- 2013-05-01
- Completion
- 2013-05-01
- First posted
- 2010-06-30
- Last updated
- 2022-05-03
- Results posted
- 2015-01-14
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01154335. Inclusion in this directory is not an endorsement.